The Catholic University of Korea Bucheon St. Mary's Hospital

Running trials

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

  NCT07919405· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both

  NCT07931547· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

  NCT07379333· Phase 3· Hanmi Pharmaceutical Company Limited· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

  NCT07230288· Phase 2· AbbVie· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Contineum Therapeutics· Source

• Recruiting

  Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus

  NCT07552389· Phase 3· Hanlim Pharm. Co., Ltd.· Source

• Recruiting

  Glycemic Variability of Combination Therapies in T2DM

  NCT07442006· Phase 4· JW Pharmaceutical· Source

• Recruiting

  A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

  NCT07202884· Phase 3· Eli Lilly and Company· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  IRIS-Coroflex NEO Cohort

  NCT06177743· Seung-Jung Park· Source

• Active, not recruiting

  A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

  NCT06588686· Phase 2· Vicore Pharma AB· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Takeda· Source

• Recruiting

  Clinical Trial on the Safety and Efficacy of Optimized Transcranial Direct Current Stimulation for the Swallowing Function in Patients With Post-Stroke Dysphagia

  NCT06305949· NEUROPHET· Source

• Active, not recruiting

  A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

  NCT06220604· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

  NCT06246123· Eisai Korea Inc.· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

  NCT06041529· Phase 4· Yuhan Corporation· Source

• Recruiting

  A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial

  NCT06141811· Anterogen Co., Ltd.· Source

• Active, not recruiting

  A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

  NCT05567796· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

  NCT05389215· Phase 2· Daewoong Pharmaceutical Co. LTD.· Source

• Active, not recruiting

  LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321420· Phase 2· PureTech· Source

• Active, not recruiting

  Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation

  NCT06247280· Yuhan Corporation· Source

• Active, not recruiting

  Timing of FFR-guided PCI for Non-IRA in STEMI and MVD (OPTION-STEMI)

  NCT04626882· Chonnam National University Hospital· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes7 recruiting
• Obesity5 recruiting
• High blood pressure3 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Chronic kidney disease1 recruiting
• Coronary artery disease1 recruiting
• Diabetic foot ulcer1 recruiting
• Rheumatoid arthritis1 recruiting
• Stroke1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Takeda· Source

• Completed

  A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06065540· Phase 3· Novo Nordisk A/S· Source

• Completed

  Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

  NCT05743907· Phase 4· Dong-A ST Co., Ltd.· Source

• Completed

  To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients With IPF

  NCT05483907· Phase 2· Bridge Biotherapeutics, Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

  NCT05718375· Phase 2· Curacle Co., Ltd.· Source

• Completed

  A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05550532· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy

  NCT05878561· Phase 3· Boryung Pharmaceutical Co., Ltd· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

  NCT05352815· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis

  NCT04541810· AbbVie· Source

• Completed

  Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis

  NCT04433442· AbbVie· Source

• Completed

  Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.

  NCT04569409· Phase 3· Anterogen Co., Ltd.· Source

• Completed

  Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

  NCT04248829· Phase 3· Yuhan Corporation· Source

• Recruiting

  Observational Study for Left Main Disease Treatment

  NCT01341327· Seung-Jung Park· Source

Conditions

Diseases this institution publishes on or runs trials for.

• High blood pressure5 works · 5 trials